LD-2 disclosure · 1st Quarter - Report
PFIZER INC.
via PFIZER INC.
Client
- Name
- PFIZER INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- PFIZER INC.
- Description
- Biopharmaceuticals
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
4 issuesCopyright/Patent/Trademark
Intellectual Property Protections
LobbyistsFRANCISCO CARRILLO
TargetedHOUSE OF REPRESENTATIVES
Health Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
LobbyistsEMILY MUELLER · FRANCISCO CARRILLO · MATTHEW STROIA · ms JENNIFER SWENSON WALTON · mrs ANGELA BOOTHE WILES
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA) · Natl Institutes of Health (NIH)
Medicare/Medicaid
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues